Clinical Trial Update: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating HepaSphere interventional therapy with digital subtraction angiography for nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• HepaSphere Interventional Therapy

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED